OptiNose, Inc. (NASDAQ:OPTN) Shares Purchased by Easterly Investment Partners LLC

Easterly Investment Partners LLC increased its holdings in OptiNose, Inc. (NASDAQ:OPTN) by 5.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,359,239 shares of the company’s stock after buying an additional 113,015 shares during the quarter. Easterly Investment Partners LLC’s holdings in OptiNose were worth $1,581,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Stonepine Capital Management LLC acquired a new stake in shares of OptiNose in the second quarter worth $2,444,000. Great Point Partners LLC grew its position in OptiNose by 56.2% during the 2nd quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock worth $14,276,000 after purchasing an additional 4,940,779 shares during the period. XTX Topco Ltd purchased a new position in shares of OptiNose during the 2nd quarter valued at about $88,000. Squarepoint Ops LLC lifted its holdings in shares of OptiNose by 173.7% in the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock valued at $178,000 after buying an additional 108,903 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of OptiNose by 2.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock worth $3,037,000 after buying an additional 81,233 shares during the last quarter. 85.60% of the stock is owned by hedge funds and other institutional investors.

OptiNose Trading Up 1.3 %

Shares of OPTN stock opened at $0.78 on Friday. OptiNose, Inc. has a twelve month low of $0.65 and a twelve month high of $2.10. The stock has a market cap of $117.61 million, a P/E ratio of -2.17 and a beta of -0.07. The stock has a 50 day moving average of $0.78 and a 200 day moving average of $0.96.

OptiNose (NASDAQ:OPTN) last posted its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $20.49 million during the quarter, compared to analyst estimates of $20.81 million. On average, research analysts predict that OptiNose, Inc. will post -0.22 earnings per share for the current fiscal year.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.